Trial Profile

Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Mar 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
15 Mar 2012 Actual initiation date changed from Mar 2008 to Jan 2008 as reported by European Clinical Trials Database.
15 Mar 2012 Planned number of patients changed from 498 to 750 as reported by European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com